Govt Approves Disinvestment of IMPCL to Skymap Pharmaceuticals for ₹121 Crore

The Government of India has approved the strategic disinvestment of Indian Medicines Pharmaceutical Corporation Limited (IMPCL), with M/s. Skymap Pharmaceuticals Private Limited emerging as the successful bidder with the highest offer of ₹121 crore.

The approval was granted by the Alternative Mechanism — a Group of Ministers empowered by the Cabinet Committee on Economic Affairs (CCEA). The panel comprised:

• Union Minister for Road Transport and Highways

• Union Finance Minister

• Union Minister of State (Independent Charge) for AYUSH

The approved bid amounts to ₹121,00,94,400 for the transfer of 100 percent equity shareholding in IMPCL along with management control.

IMPCL Established to Promote Ayurvedic and Unani Medicines

Indian Medicines Pharmaceutical Corporation Limited (IMPCL) was incorporated on 12 July 1978 with the objective of manufacturing and supplying standardized Ayurvedic and Unani medicines.

The company has historically played an important role in supporting India’s traditional medicine ecosystem by supplying medicines for government healthcare programmes and AYUSH institutions.

The strategic disinvestment forms part of the government’s broader public sector disinvestment and asset monetisation policy aimed at improving operational efficiency, encouraging private investment, and unlocking value from public enterprises.

Strategic Disinvestment Approved in 2017

The Cabinet Committee on Economic Affairs had granted “in-principle” approval in November 2017 for the strategic disinvestment of the government’s entire equity stake in IMPCL.

The government decided to transfer ownership and management control to a strategic buyer identified through a transparent two-stage bidding process.

Officials stated that the transaction was carried out through a competitive and multi-layered consultative framework involving various government departments and expert advisors.

Extensive Competitive Bidding Process Conducted

The strategic disinvestment process involved appointment of professional advisers including:

• Transaction Adviser

• Legal Adviser

• Asset Valuer

The Preliminary Information Memorandum (PIM) inviting Expressions of Interest (EoI) from prospective bidders was issued on 1 September 2023.

In response, seven interested parties submitted expressions of interest, all of which were shortlisted as qualified bidders.

Following shortlisting, the Qualified Interested Bidders (QIBs) conducted due diligence and security clearances were obtained from the Ministry of Home Affairs.

Request for Proposal Issued in 2025

The Request for Proposal (RFP), along with the Share Purchase Agreement (SPA) detailing terms and conditions of the transaction, was issued on 1 December 2025.

Qualified bidders were invited to submit both technical and financial bids.

By the due date of 20 January 2026, two sealed financial bids had been received from qualified bidders.

Officials stated that both bids were evaluated according to the prescribed procedures and were found technically qualified.

Skymap Pharmaceuticals Emerges Highest Bidder

After technical qualification, the financial bids were opened in the presence of representatives from the participating companies.

M/s. Skymap Pharmaceuticals Private Limited emerged as the highest bidder with an offer of:

₹121,00,94,400

Officials confirmed that the bid was also above the reserve price fixed for the transaction.

The government has since issued the Letter of Award to the successful bidder.

Multi-Layered Decision-Making Mechanism Followed

According to the government, the strategic disinvestment process was conducted through a transparent, open, and competitive bidding mechanism supported by multiple levels of institutional review.

The process involved consultations and approvals through:

• Inter-Ministerial Group (IMG)

• Core Group of Secretaries on Disinvestment

• Empowered Alternative Mechanism

The transaction structure was designed to ensure transparency, fairness, and compliance with government disinvestment procedures.

DIPAM and AYUSH Ministries to Complete Transaction

The government stated that the Secretary of the Department of Investment and Public Asset Management (DIPAM) and the Secretary of the Ministry of AYUSH have been authorised to complete and close the transaction at the earliest.

Officials are expected to oversee the transfer of ownership, equity, and management control as part of the final implementation process.

Strategic Importance of AYUSH and Traditional Medicine Sector

IMPCL operates within India’s growing AYUSH sector, which includes:

• Ayurveda

• Yoga

• Naturopathy

• Unani

• Siddha

• Homeopathy

India has increasingly promoted traditional medicine systems both domestically and internationally through various policy initiatives, research programmes, and global wellness outreach efforts.

The AYUSH industry has witnessed rapid growth in recent years due to rising global interest in:

• Holistic healthcare

• Herbal medicines

• Preventive wellness

• Traditional therapeutic systems

Government Continuing Public Sector Reforms

The strategic disinvestment of IMPCL reflects the government’s ongoing efforts to reform and rationalize public sector enterprises through:

• Strategic disinvestment

• Privatization

• Asset monetisation

• Operational restructuring

• Public-private participation

Officials argue that strategic disinvestment can help improve operational efficiency, attract fresh investment, strengthen competitiveness, and reduce administrative burdens on the government.

At the same time, analysts note that sectors linked to healthcare and traditional medicine remain strategically important given India’s expanding global influence in wellness and AYUSH-related industries.

Growing Market for Traditional Medicines

India’s traditional medicine sector is increasingly becoming an important contributor to the country’s healthcare and export economy.

The government has been promoting AYUSH-based healthcare systems through initiatives involving:

• Research and standardization

• International collaborations

• Medical tourism

• Digital health integration

• Herbal product exports

• AYUSH infrastructure development

Experts believe that private sector participation in companies like IMPCL may potentially support modernization, product expansion, innovation, and improved manufacturing capabilities within the traditional medicine sector.